InPharm reports that AstraZeneca's Zactima was approved by the FDA as an orphan drug for the treatment of a rare thyroid cancer (represents 3-5% of all thyroid cancers). The drug is also under regulatory review in Europe.
Zactima (vandetanib) is AZ's first orphan drug approval.
“Vandetanib’s approval underscores FDA’s commitment to approving treatments for patients with rare and difficult to treat diseases,” said Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research.
Posted by Bruce Lehr April 8th 2011.